Xilio Therapeutics (NASDAQ:XLO) Issues Earnings Results

by · The Cerbat Gem

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) announced its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08), FiscalAI reports. The company had revenue of $19.07 million during the quarter, compared to the consensus estimate of $18.64 million. Xilio Therapeutics had a negative net margin of 374.79% and a negative return on equity of 399.15%.

Xilio Therapeutics Stock Down 11.3%

Shares of Xilio Therapeutics stock traded down $0.09 during trading on Thursday, hitting $0.69. 1,215,381 shares of the stock traded hands, compared to its average volume of 1,727,279. The stock has a market cap of $35.56 million, a price-to-earnings ratio of -0.91 and a beta of -0.08. The firm’s fifty day moving average is $0.78 and its 200-day moving average is $0.75. Xilio Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.70.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Leerink Partnrs raised Xilio Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 6th. Leerink Partners initiated coverage on shares of Xilio Therapeutics in a research report on Wednesday, August 6th. They set an “outperform” rating and a $2.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Xilio Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xilio Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $2.00.

View Our Latest Stock Analysis on Xilio Therapeutics

Xilio Therapeutics Company Profile

(Get Free Report)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.

Featured Articles